Abstract
Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Current Drug Safety
Title: Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab
Volume: 6 Issue: 5
Author(s): Gregory Owens and Andrej Petrov
Affiliation:
Keywords: Asthma, omalizumab, hypersensitivity, desensitization, IgG1 monoclonal antibody, LABA therapy
Abstract: Background: Omalizumab is prescribed as a step-up therapy for patients with moderate to severe allergic asthma uncontrolled on high-dose inhaled corticosteroids and long acting beta agonists. However, hypersensitivity reactions may lead to its discontinuation and subsequent worsening or loss of asthma control. No successful desensitization protocols to omalizumab have been previously reported.
Objective: We aimed to determine the efficacy and safety of a novel one-day outpatient omalizumab desensitization protocol for patients with hypersensitivity reactions to omalizumab.
Methods: We retrospectively assessed the efficacy of omalizumab desensitization protocol performed in a university allergy-immunology clinic from July 2009 to July 2010.
Results: We successfully desensitized 3 patients with moderate-severe asthma to omalizumab. After desensitization all patients had improvement in asthma control and were able to discontinue or decrease chronic systemic steroid therapy.
Conclusions: This novel outpatient omalizumab desensitization protocol was a safe and effective approach for the treatment of omalizumab hypersensitivity in patients with moderate to severe allergic asthma who required omalizumab therapy.
Export Options
About this article
Cite this article as:
Owens Gregory and Petrov Andrej, Successful Desensitization of Three Patients with Hypersensitivity Reactions to Omalizumab, Current Drug Safety 2011; 6 (5) . https://dx.doi.org/10.2174/157488611798918692
DOI https://dx.doi.org/10.2174/157488611798918692 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SARS-CoV-2 & Covid-19: Key-Roles of the ‘Renin-Angiotensin’ System / Vitamin D Impacting Drug and Vaccine Developments
Infectious Disorders - Drug Targets Chemokines and Their Receptors in Chronic Pulmonary Disease
Current Drug Targets - Inflammation & Allergy Herbal Nano Formulations: Patent and Regulatory Overview
Applied Clinical Research, Clinical Trials and Regulatory Affairs Transcriptional Regulation of Inflammatory Genes Associated with Severe Asthma
Current Pharmaceutical Design Chemical Profile and Anticancer Activity of Polyscias guilfoylei Leaf Essential Oil
The Natural Products Journal Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis
Current Drug Targets Immunobiology of Antigen-Specific Immunoglobulin Free Light Chains in Chronic Inflammatory Diseases
Current Pharmaceutical Design Editorial [Hot Topic:Metalloproteinases Revisited (Guest Editor: Marcia L. Moss)]
Current Pharmaceutical Biotechnology Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Lung Dendritic Cells: Targets for Therapy in Allergic Disease
Current Molecular Medicine Oxidative Stress in Allergic and Irritant Dermatitis: From Basic Research to Clinical Management
Recent Patents on Inflammation & Allergy Drug Discovery Hypersensitivity to Aspirin and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Current Pharmaceutical Design Editorial (Thematic Issue: Vitamin D and Vitamin D Receptor in Asthma and Allergy)
Mini-Reviews in Medicinal Chemistry Bronchial Asthma, Chronic Obstructive Pulmonary Disease and NF-κB
Current Medicinal Chemistry A Novel Antidiabetic Therapy: Free Fatty Acid Receptors as Potential Drug Target
Current Diabetes Reviews Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Optimization of Site Targeted Zolmitriptan Delivery Using Polyox N12K and Methacrylic Acid
Current Drug Therapy Photo-Sensitive Liposomes: Chemistry and Application in Drug Delivery
Mini-Reviews in Medicinal Chemistry Oesophagogastric Disconnection: Who, How and When? A Review Article
Current Pediatric Reviews Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry